Sakalis Vasileios I, Campi Riccardo, Barreto Lenka, Perdomo Herney Garcia, Greco Isabella, Zapala Łukasz, Kailavasan Mithun, Antunes-Lopes Tiago, Marcus Jack David, Manzie Kenneth, Osborne John, Ayres Benjamin, Moonen Luc M F, Necchi Andrea, Crook Juanita, Oliveira Pedro, Pagliaro Lance C, Protzel Chris, Parnham Arie S, Albersen Maarten, Pettaway Curtis A, Spiess Philippe E, Tagawa Scott T, Rumble R Bryan, Brouwer Oscar R
Department of Urology, Agios Pavlos General Hospital, Thessaloniki, Greece.
Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi University Hospital, San Luca Nuovo, Florence, Italy.
Eur Urol Open Sci. 2022 May 2;40:58-94. doi: 10.1016/j.euros.2022.04.002. eCollection 2022 Jun.
The primary lesion in penile cancer is managed by surgery or radiation. Surgical options include penile-sparing surgery, amputative surgery, laser excision, and Moh's micrographic surgery. Radiation is applied as external beam radiotherapy (EBRT) and brachytherapy. The treatment aims to completely remove the primary lesion and preserve a sufficient functional penile stump.
To assess whether the 5-yr recurrence-free rate and other outcomes, such as sexual function, quality of life, urination, and penile preserving length, vary between various treatment options.
The EMBASE, MEDLINE, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials (CENTRAL; Cochrane HTA, DARE, HEED), Google Scholar, and ClinicalTrials.gov were searched for publications from 1990 through May 2021. Randomized controlled trials, nonrandomized comparative studies (NRCSs), and case series (CSs) were included.
The systematic review included 88 studies, involving 9578 men from 16 NRCSs and 72 CSs. The cumulative mean 5-yr recurrence-free rates were 82.0% for penile-sparing surgery, 83.9% for amputative surgery, 78.6% for brachytherapy, 55.2% for EBRT, 69.4% for lasers, and 88.2% for Moh's micrographic surgery, as reported from CSs, and 76.7% for penile-sparing surgery and 93.3% for amputative surgery, as reported from NRCSs. Penile surgery affects sexual function, but amputative surgery causes more appearance concerns. After brachytherapy, 25% of patients reported sexual dysfunction. Both penile-sparing surgery and amputative surgery affect all aspects of psychosocial well-being.
Despite the poor quality of evidence, data suggest that penile-sparing surgery is not inferior to amputative surgery in terms of recurrence rates in selected patients. Based on the available information, however, broadly applicable recommendations cannot be made; appropriate patient selection accounts for the relative success of all the available methods.
We reviewed the evidence of various techniques to treat penile tumor and assessed their effectiveness in oncologic control and their functional outcomes. Penile-sparing as well as amputative surgery is an effective treatment option, but amputative surgery has a negative impact on sexual function. Penile-sparing surgery and radiotherapy are associated with a higher risk of local recurrence, but preserve sexual function and quality of life better. Laser and Moh's micrographic surgery could be used for smaller lesions.
阴茎癌的原发性病变通过手术或放疗进行治疗。手术选择包括保留阴茎手术、截肢手术、激光切除和莫氏显微外科手术。放疗采用外照射放疗(EBRT)和近距离放疗。治疗目的是完全切除原发性病变并保留足够功能的阴茎残端。
评估不同治疗方案之间5年无复发生存率以及其他结局,如性功能、生活质量、排尿情况和阴茎保留长度是否存在差异。
检索了EMBASE、MEDLINE、Cochrane系统评价数据库、Cochrane对照试验中心注册库(CENTRAL;Cochrane卫生技术评估数据库、DARE数据库、HEED数据库)、谷歌学术和ClinicalTrials.gov,查找1990年至2021年5月期间的出版物。纳入随机对照试验、非随机对照研究(NRCSs)和病例系列(CSs)。
该系统评价纳入了88项研究,涉及来自16项NRCSs和72项CSs的9578名男性。病例系列报告的保留阴茎手术、截肢手术、近距离放疗、EBRT、激光治疗和莫氏显微外科手术的累积平均5年无复发生存率分别为82.0%、83.9%、78.6%、55.2%、69.4%和88.2%,非随机对照研究报告的保留阴茎手术和截肢手术的累积平均5年无复发生存率分别为76.7%和93.3%。阴茎手术会影响性功能,但截肢手术会引起更多外观方面的担忧。近距离放疗后,25%的患者报告存在性功能障碍。保留阴茎手术和截肢手术都会影响心理社会幸福感的各个方面。
尽管证据质量较差,但数据表明在特定患者中,保留阴茎手术在复发率方面并不逊于截肢手术。然而,基于现有信息,无法给出广泛适用的建议;合适的患者选择是所有可用方法取得相对成功的关键。
我们回顾了治疗阴茎肿瘤的各种技术的证据,并评估了它们在肿瘤控制和功能结局方面的有效性。保留阴茎手术和截肢手术都是有效的治疗选择,但截肢手术对性功能有负面影响。保留阴茎手术和放疗局部复发风险较高,但能更好地保留性功能和生活质量。激光和莫氏显微外科手术可用于较小的病变。